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Early reports from China found that both established cardiovascular 
disease and its risk factors, such as hypertension and diabetes mel-
litus, were common pre-existing conditions in patients with COVID-
19.1,2 The high prevalence of these comorbidities was confirmed in 
subsequent studies.3 Remarkably, the prevalence of these pre-ex-
isting conditions was higher in critically ill patients and in those who 
died.2,4,5 In the analysis performed by Wu and McGoogan, including 
44 672 patients with confirmed COVID-19, the overall case fatality 
rate was 2.3%, and increased with comorbid conditions: 10.5% for 
cardiovascular disease, 7.3% for diabetes, and 6% for hypertension.6 
The connections between cardiovascular disease, hypertension, age, 
and vascular aging are complex. The association between hyperten-
sion and COVID-19 mortality or severity could be explained in part 
by the increased age and higher prevalence of cardiovascular dis-
ease, both well-known risk factors for mortality in critical patients. 
Therefore, in order to identify independent predictors of COVID-19 
mortality or severity, models should be properly adjusted to exclude 
potential confounding effects.7
The study by Sun and colleagues8 published in The Journal of 
Clinical Hypertension added new information to this relevant topic. 
They performed a retrospective analysis of 3400 adults with con-
firmed COVID-19 hospitalized at two hospitals in Wuhan, China. 
Patients with type 1 diabetes mellitus were excluded. The authors 
used a multivariate logistic analysis in order to estimate the effect 
of hypertension, type 2 diabetes mellitus and their combination on 
the risk of developing death (it was the primary outcome), respira-
tory failure, and severe COVID-19 infection. Compared to patients 
having neither hypertension nor diabetes, the risk of mortality was 
significantly higher in patients with diabetes alone (OR 5.26 [95% CI: 
2.39–12 11.58]) or with diabetes in combination with hypertension 
(OR 3.02, [95% CI: 1.48–6.15]). Moreover, diabetes was a risk fac-
tor for development of respiratory failure and severe infection, but 
hypertension alone only conferred the risk for the development of 
severe infection (OR 1.22 [95% CI: 1.00–1.51]). Advanced age, male 
sex, history of cardiovascular diseases, and chronic kidney disease 
were also independent risk factors for adverse outcomes. To exclude 
possible confounding effects of these comorbid conditions, the au-
thors performed a sensitivity analysis among 2304 patients who did 
not have any other identified comorbidities beyond hypertension or 
diabetes. This analysis confirmed that diabetes, but not hyperten-
sion, increased the risk of death.
The lack of relationship between hypertension and severe/
lethal COVID-19 found by Sun and colleagues8 was contradictory 
with some previously published studies. Guan et al found in 1099 
patients with confirmed COVID-19 that hypertension was a more 
prevalent condition in those who had a primary composite end point 
(admission to critical care unit, use of mechanical ventilation or 
death), 35.8% versus 13.7%.5 Ruan and colleagues also described in 
150 patients with confirmed COVID-19 that cardiovascular disease 
and hypertension were more frequent in patients who died com-
pared with those who were discharged (19% versus 0%, P < .001, 
and 43% versus 28%, P = .07, respectively).9 Moreover, a system-
atic review and meta-analysis that included 46 248 infected pa-
tients found that hypertension was associated with COVID-19 poor 
outcome (OR 2.36 [95% CI 1.46–3.83]).10 However, none of these 
studies performed a multivariable adjustment. Guan and colleagues 
found, using Cox regression model, that both hypertension (HR 
1.58, 95% CI 1.07–2.32) and diabetes (HR 1.59, 95% CI 1.03–2.45) 
were predictors for poor outcome to a similar degree.11 However, 
the adjustment was only performed for age and smoking. Thus, the 
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effect of arterial hypertension on the severity or mortality could 
be explained by potential confounders. Rodilla and colleagues, in a 
retrospective analysis of 12 226 patients who required hospital ad-
mission in Spain, found that hypertension, diabetes, coronary heart 
disease, heart failure, atrial fibrillation, stroke, and chronic kidney 
disease were significantly more frequent in non-survivals.12 Using 
multivariable analysis adjusted for age and sex, the authors stated 
that pre-existing hypertension (but not diabetes) had an indepen-
dent prognostic value for mortality in patients with COVID-19 who 
required hospitalization.
On the other hand, data of some studies using multivariate logis-
tic regression models to identify independent clinical predictors for 
mortality or severity support the results of Sun and colleagues The 
studies by Chen and colleagues13 and by Zhou and colleagues2 found 
that hypertension was a predictor of COVID-19 severity or mortal-
ity in the univariate analysis; in both studies, however, hypertension 
was not an independent predictor of risk in the multivariate logis-
tic regression model. Moreover, the Italian Society of Hypertension 
performed a cross-sectional, observational, multicenter, nationwide 
survey including 1591 patients diagnosed with COVID-19, admitted 
in 26 hospitals. Older age, hypertension, diabetes mellitus, chronic 
obstructive pulmonary disease, chronic kidney disease, coronary 
artery diseases, and heart failure were more frequent in non-sur-
vivors than in survivors. After adjustment for multivariate analy-
sis, age (P = .0001), diabetes (P = .004), and chronic kidney disease 
(P = .004), but not hypertension, predicted mortality.14 Remarkably, 
in this study, the prevalence of hypertension among COVID-19 pa-
tients is comparable to that expected based on the data recorded 
in the general population during the World Hypertension Day in 
Italy from 2010 to 2018. A meta-analysis including 16 studies with 
3994 patients shows that hypertension (OR 2.95), diabetes mellitus 
(OR 3.07), cardiovascular disease (OR 4.58), and chronic kidney dis-
ease (OR 5.32) lead to a higher risk of developing serious events. 
However, diabetes mellitus (OR 2.78) but not hypertension had a 
significant impact on the mortality rate.15
While the roll of hypertension without any other comorbidities 
in predicting death among COVID-19 patients seems debatable, dia-
betes appears as a well-established risk factor. The results found by 
Sun and colleagues8 was consistent with many previously published 
studies. Since the initial COVID-19 outbreak in China several retro-
spective studies,11,16,17 cohort studies,18 and metanalysis19 support 
the association between diabetes and COVID-19 mortality or sever-
ity. Although initial reports were mainly on people with type 2 diabe-
tes, recent surveys have shown that individuals with type 1 diabetes 
are also at risk of severe COVID-19.18
However, individuals with diabetes often had comorbidities such 
as hypertension, obesity, and cardiovascular disease. In a retrospec-
tive analysis of patients with COVID-19, those with diabetes had a 
greater prevalence of hypertension (56.9% vs 28.8%), cardiovas-
cular disease (20.9% vs 11.1%), and cerebrovascular disease (7.8% 
vs 1.3%) than those without diabetes.18 Moreover, specifically in 
patients with diabetes, non-survivors had a greater prevalence of 
comorbidities than survivors. Consistent with the study by Sun and 
colleagues,8 in a Cox regression analysis performed on patients with 
diabetes hypertension was and independent risk factor for in-hospi-
tal death (HR 3.10, 95% CI 1.14–8.44).18
Remarkably, in most studies, cardiovascular disease was strongly 
associated with poor COVID-19 outcome in univariate and multivar-
iate analysis. The prevalence of diabetes, hypertension, and cardio-
vascular disease increases with age and frequently coexists in the 
same patient. Thus, age, vascular aging, and cardiovascular disease 
could be a linchpin between diabetes, hypertension, and COVID-19 
poor outcomes.
Beyond the controversies regarding which are independent 
predictors for risk, in the clinical practice hypertension, diabetes, 
and chronic cardiac and renal disease identify a subset of subjects 
at risk of developing severe COVID-19. However, for some clin-
ical decisions, a fine-tuning of our knowledge could be necessary. 
Understanding the clinical characteristics that anticipate the worse 
outcome of COVID-19 is necessary for an appropriate use of the 
resources. For instance, when effective vaccines become available, 
priorities for vaccination should be defined. In this context, to iden-
tify independent risk factors appears as a critical issue, especially if 
a supposed risk factor is highly prevalent. Hypertension is the most 
prevalent risk factor: roughly one-third of the population in devel-
oped and developing countries is expected to be affected by this 
condition; the global prevalence of hypertension was estimated to 
be 1.13 billion in 2015.20 Also, in many regions, >60% of the popu-
lation above 60 years old is hypertensive.21 While individuals with 
diabetes and/or established cardiovascular disease undoubtedly 
emerge as priorities for vaccination, the risk of individuals with hy-
pertension without established cardiovascular disease or end-organ 
damage seems less well defined.
In this matter, the study of Sun and colleagues8 does not sup-
port a significant effect of hypertension on COVID-19 mortality. 
However, their conclusion should not be generalized for many rea-
sons. First, it was a retrospective analysis performed in two hospitals 
of a single region of China. The prevalence of hypertension varies 
widely between ethnic groups and regions. Moreover, regional dif-
ferences in the level of hypertension knowledge, treatment and 
control could modify the prevalence of established cardiovascular 
disease and, in consequence, the risk for severe or fatal COVID-19. 
Second, the study had a surprisingly low rate of fatal events, and 
comparisons with other studies could be non-appropriate. For ex-
ample, the study by Rodilla and colleagues12 had 10 times higher 
mortality than the study by Sun and colleagues8 Also, the scarce 
number of fatal events made the multivariable analysis less confi-
dent. Finally, since it was a retrospective analysis, several sources of 
bias related with levels of blood pressure, treatments and end-organ 
damage cannot be discharged. The possibility of this bias was sug-
gested by the unexpected lower risk of diabetes plus hypertension 
compared to diabetes alone. Beyond these limitations, the study by 
Sun and colleagues8 highlights the importance of encouraging the 
development of regional well designed, multivariable adjusted stud-
ies in order to identify accurate predictors for severe or fatal COVID-
19 on different populations.
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In conclusion and regarding the initial question, “Is hypertension 
an independent predictor of COVID-19 severity and mortality?” I 
believe that we cannot count on a single answer for the wide spec-
trum of patients with hypertension. Thus, it is probable that the 
answer will vary according to the severity of hypertension and the 
presence of other risk factors, such as end-organ damage or estab-
lished cardiovascular disease. Also, the published analysis was based 
on self-reported or casual and office blood pressure recordings; the 
presence of white coat and masked hypertension could modify the 
relationship between hypertension and COVID-19 poor outcomes. 
Finally, hypertension prevalence increases with age as well, and so 
do other risk factors, such as diabetes mellitus, chronic kidney dis-
ease, and cardiovascular disease. How to correct the effect caused 
by age, established end-organ damage, level of blood pressure and 
treatments, is an unresolved issue; possibly due to the high collinear-
ity of these conditions and the inherent limitations of multivariate 
regression analysis.
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